Avidian Wealth Enterprises’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Avidian Wealth Enterprises’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-106,000	Closed	-$493K	–	596
2021 Q4	$493K	Sell	106,000 -3,000	-3%	-$18.6K	0.03%	303
2021 Q3	$832K	Sell	109,000 -40	-0%	-$339	0.06%	150
2021 Q2	$1.06M	Sell	109,040 -81,000	-43%	-$645K	0.08%	128
2021 Q1	$1.57M	Sell	190,040 -387,460	-67%	-$4.09M	0.13%	93
2020 Q4	$3.94M	Buy	577,500 +412,500	+250%	+$3.31M	0.37%	46
2020 Q3	$1.84M	Buy	+165,000	New	+$1.51M	0.21%	73

Other funds holding SRNE

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Avidian Wealth Enterprises's SRNE Position: Q1 2022 in Review

Avidian Wealth Enterprises sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2022, closing a stake of 106,000 shares — an estimated $493K sold.

Avidian Wealth Enterprises first reported a position in SRNE in Q3 2020 and held it in 6 quarters. The position peaked at $3.94M in Q4 2020. 235 funds tracked by Wall St. Rank hold SRNE as of Q1 2022.

Avidian Wealth Enterprises reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
Avidian Wealth Enterprises sold 106,000 Sorrento Therapeutics, Inc. shares in Q1 2022, an estimated $493K.
Avidian Wealth Enterprises first reported a position in Sorrento Therapeutics, Inc. in Q3 2020 and held it in 6 quarters.
Avidian Wealth Enterprises's Sorrento Therapeutics, Inc. position peaked at $3.94M in Q4 2020.
235 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2022.

Based on Avidian Wealth Enterprises's 13F filing for Q1 2022, filed 10 May 2022.